依维莫司二线治疗晚期肾细胞癌12例临床观察  

Clinical study of everolimus treatment of 12 patients with metastatic renal cell carcinoma

作　　者：朱华云[1] 孙小峰[1] 李薇[2] 陈嘉[1] 吴平平[1] 邹青[3] 

机构地区：[1]江苏省肿瘤医院肿瘤内科,南京210009 [2]江苏省人民医院肿瘤内科 [3]江苏省肿瘤医院泌尿外科

出　　处：《现代泌尿生殖肿瘤杂志》2015年第3期149-151,共3页Journal of Contemporary Urologic and Reproductive Oncology

摘　　要：目的评估依维莫司治疗转移性肾癌的疗效和安全性。方法回顾性分析2013年6月至2014年6月应用依维莫司治疗的12例转移性肾癌患者的资料,主要观察指标为客观有效率、临床获益率、中位无疾病进展时间和不良反应发生率。结果所有入组患者均完成至少2个周期治疗。客观缓解率0,疾病控制率83.3%,平均中位无进展生存期为6.67个月。常见不良反应有乏力、恶心、腹泻、咳嗽、发热、贫血、皮疹、口腔溃疡、血糖升高等,其中Ⅲ～Ⅳ级有6人次,造成中断治疗2例（16.7%）。结论依维莫司治疗转移性肾癌近期和远期疗效良好,但不良反应相对较大,需密切关注。Objective To evaluate the efficacy and safety of everolimus in the treatment of metastatic renal cell carcinoma （mRCC）. Methods The clinical date of 12 patients with mRCC from June 2013 to June 2014 was retrospectively reviewed. The clinical indexes were objective response rate, clinical benefit rate, median time of progression-free survival （PFS） and the incidence of adverse reaction. Results All enrolled patients completed two cycles of treatment at least. The objective response rate was 0, the disease control rate was 83.3%, while the median time of PFS was 6.67 months. The common adverse reactions included fatigue, nausea, diarrhea, cough, fever, anemia, skin rashes, mouth ulcers, high blood sugar. Among them, Ⅲ-Ⅳ grade adverse reaction took place on 6 patients, which interrupted the treatment of 2 patients （16.7%）. Conclusions Everoli- mus has good short- and long-term efficacy for patients with mRCC, but adverse reactions were relatively serious, which needs careful observation during the period of treatment.

关 键 词：依维莫司 肾癌 靶向治疗 

分 类 号：R737.11[医药卫生—肿瘤]